RecruitingNCT06592196

Hepatic Safety of Statin Use in Neurology Inpatients

A Retrospective Study on the Hepatic Safety of Statin Use in Neurology Inpatients


Sponsor

Shanghai Yueyang Integrated Medicine Hospital

Enrollment

2,000 participants

Start Date

Aug 10, 2024

Study Type

OBSERVATIONAL

Conditions

Summary

This research employs a cross-sectional study and a retrospective cohort study to analyze the liver safety of statin use among inpatients in the neurology department in China from different perspectives. The aim is to supplement evidence-based medicine and provide guidance for the clinical use of statins.


Eligibility

Min Age: 18 YearsMax Age: 85 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying stain for people with statin adverse reaction. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 85 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERstain

This research was conducted in two phases. Initially, a cross-sectional study was performed to assess the correlation between statin usage prior to hospital admission and the initial state of liver enzymes among patients. Subsequently, a retrospective cohort study was undertaken, wherein patients who had not been on statins prior to admission were categorized into two groups based on their statin usage post-admission.


Locations(1)

Shanghai Yueyang Integrated Medicine Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06592196


Related Trials